Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 12/20 | 1.00 |
| ▸ | MAPT | P10636 | 12/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 11/20 | 1.00 |
| ▸ | HPGD | P15428 | 11/20 | 1.00 |
| ▸ | RAB9A | P51151 | 10/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 7/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 7/20 | 1.00 |
| ▸ | RELA | Q04206 | 7/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 15/20 | 0.81 |
| ▸ | MEN1 | O00255 | 14/20 | 0.81 |
| ▸ | NPC1 | O15118 | 9/20 | 0.81 |
| ▸ | TP53 | P04637 | 4/20 | 0.81 |
| ▸ | LMNA | P02545 | 4/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.81 |
| ▸ | GLA | P06280 | 1/20 | 0.81 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.81 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17938574 | 0.88 | MEN1 (0.78) | SMN1; SMN2MAPTALOX15HPGDRAB9A | |
| SCHEMBL10358110 | 0.88 | MAPT (1.00) | SMN1; SMN2MAPTALOX15HPGDRAB9A | |
| SCHEMBL17280247 | 0.86 | ALOX15 (0.75) | SMN1; SMN2MAPTALOX15HPGDRAB9A | |
| SCHEMBL10357883 | 0.86 | MAPT (0.76) | SMN1; SMN2MAPTALOX15HPGDRAB9A | |
| SCHEMBL10357282 | 0.85 | KMT2A (0.89) | SMN1; SMN2MAPTALOX15HPGDRAB9A | |
| SCHEMBL10358038 | 0.84 | KMT2A (0.79) | SMN1; SMN2MAPTALOX15HPGDRAB9A | |
| SCHEMBL10357379 | 0.83 | KMT2A (0.76) | SMN1; SMN2MAPTALOX15HPGDRAB9A | |
| SCHEMBL17279997 | 0.81 | RAB9A (0.69) | SMN1; SMN2MAPTALOX15HPGDRAB9A | |
| SCHEMBL24299072 | 0.81 | HPGD (0.68) | SMN1; SMN2MAPTALOX15HPGDRAB9A | |
| SCHEMBL10357782 | 0.81 | MAPT (0.68) | SMN1; SMN2MAPTALOX15HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299131-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NATIONAL INSTITUTES OF HEALTH | 2021-09-30 | — | — | US | disclosed |
| US-10953017-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200171040-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RES INST (US) | 2020-06-04 | — | — | US | disclosed |
| US-20190083505-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NATIONAL INSTITUTES OF HEALTH | 2019-03-21 | — | — | US | disclosed |
| US-9980969-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2018-05-29 | — | — | US | disclosed |
| US-9980969-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2018-05-29 | — | — | US | disclosed |
| US-20160022691-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RES INST (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160022691-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RES INST (US) | 2016-01-28 | — | — | US | disclosed |
| US-9095596-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2015-08-04 | — | — | US | disclosed |
| US-9095596-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2015-08-04 | — | — | US | disclosed |
| US-20120245166-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RESEARCH INSTITUTE (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245166-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RESEARCH INSTITUTE (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120184583-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184583-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2011047129-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RESEARCH INSTITUTE (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20100144798-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144798-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022691-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | SMN1; SMN2 33/4885MAPT 54/4885ALOX15 202/4885 |
| US-20120184583-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | SMN1; SMN2 4852/4885MAPT 4385/4885ALOX15 3215/4885 |
| US-20200171040-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | SMN1; SMN2 29/4885MAPT 56/4885ALOX15 177/4885 |
| US-20100144798-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | SMN1; SMN2 4852/4885MAPT 4385/4885ALOX15 3215/4885 |
| US-20190083505-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | SMN1; SMN2 29/4885MAPT 56/4885ALOX15 177/4885 |
| US-20210299131-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | SMN1; SMN2 29/4885MAPT 56/4885ALOX15 177/4885 |
| US-20120245166-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | SMN1; SMN2 29/4885MAPT 56/4885ALOX15 177/4885 |
| US-10953017-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | NFKBIA, NFRKB, TFEB | SMN1; SMN2 29/4885MAPT 56/4885ALOX15 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.